Proteinase activity regulation by glycosaminoglycans

Brazilian Journal of Medical and Biological Research

Volumn 35, Issue 2, 2002, Pages 135-144

  Tersariol, I L S ^a   Pimenta, D C ^b   Chagas, J R ^a   Almeida, P C ^a  

^a UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Glycosaminoglycan; Heparin binding; Macromolecules; Proteinases

Indexed keywords

ASPARTIC PROTEINASE; CARBOHYDRATE; CYSTEINE PROTEINASE; GLYCOSAMINOGLYCAN; METALLOPROTEINASE; PROTEINASE; SERINE PROTEINASE;

AMINO ACID SEQUENCE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME LOCALIZATION; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN FAMILY; TISSUE INJURY;

EID: 0036118590     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2002000200001     Document Type: Article

References (58)

1. Cysteine proteinase activity regulation. A possible role of heparin and heparin-like glycosaminoglycans
2. Cathepsin B activity regulation. Heparin-like glycosaminoglycans protect human cathepsin B from alkaline pH-induced inactivation
3. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates
4. Heparin accelerates the inhibition of cathepsin G by mucus proteinase inhibitor: Potent effect of O-butyrylated heparin
5. Demonstration of a two-step reaction mechanism for inhibition of heparin-bound neutrophil elastase by alpha1-proteinase inhibitor
6. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor Xla
7. Chymase bound to heparin is resistant to its natural inhibitors and capable of proteolyzing high density lipoproteins in aortic intimal fluid
8. Identification of the antithrombin III heparin binding site
9. Mechanism of heparin activation of antithrombin
10. Identification of a major heparin-binding site in kallistatin
11. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions
12. Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma
13. Proteases in cellular regulation
14. Evolutionary families of peptidases
15. Regulated diversity of heparan sulfate
16. Structural differences of heparan sulfates according to the tissue and species of origin
17. Structure of heparan sulfate: Identification of variable and constant oligosaccharide domains in eight heparan sulfates of different origins
18. Cell surface heparan sulfate proteoglycans
19. Integral membrane heparan sulfate proteoglycans
20. The biology of perlecan: The multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices
21. Heparin-Binding Proteins
22. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation
23. Heparin protects cathepsin G against inhibition by protein proteinase inhibitors
24. Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids
25. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin
26. Effects of glycosaminoglycans on factor XI activation by thrombin
27. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement
28. Binding of a de novo designed peptide to specific glycosaminoglycans
29. Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models
30. Alpha1-antichymotrypsin and kallistatin hydrolysis by human cathepsin D
31. Moledular modeling of protein-glycosaminoglycan interactions
32. Neutrophil elastase and cathepsin G: Structure, function, and biological control
33. New approaches to the management of COPD
34. Oxidative autoaggression by phagocytes in human peritonitis
35. Effect of DNase on the activity of neutrophil elastase cathepsin G and proteinase 3 in the presence of DNA
36. Roles of P1, P2 and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein
37. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity
38. cDNA cloning and expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinases
39. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP-3 gene to chromosome 22
40. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase-4
41. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3
42. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix
43. Pentosan polysulfate decreases proliferation and net extracellular matrix production in mouse mesangial cells
44. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues
45. Substrate specificity of human cathepsin D using internally quenched fluorescent peptides derived from reactive site loop of kallistatin
46. Kininogenase activity by the major cysteinyl proteinase (cruzipain) from Trypanosoma cruzi
47. Cathepsin B: Association with plasma membrane in metastatic tumors
48. Suicidal tumor proteases
49. Medical Aspects of Protease and Protease Inhibitors
50. Mannose-6-phosphate receptors for lysosomal enzyme cycle between the Golgi complex and endosomes
51. Neither type of mannose 6-phosphate receptor is sufficient for targeting of lysosomal enzymes along intracellular routes
52. Elevations in cathepsin B protein content and enzyme activity occur independently of glycosylation during colorectal tumor progression
53. Biosynthesis of cathepsin B in cultured normal and l-cell fibroblasts
54. Differentiation-induced changes in the content, secretion, and subcellular distribution of lysosomal cathepsins in the human colon cancer HT-29 cell line
55. Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer
56. Caspase-dependent and -independent death pathways in cancer therapy
57. Blood coagulation
58. Emerging treatments for hypertension: Potential role for vasopeptidase inhibition